Announcement PDF ASX ANNOUNCEMENT INTERNATIONAL PATENT COVERING INV043 TO EXTEND IP PROTECTION FOR PHOTOSOFTTM Highlights: • • • • • International patent published covering clinical drug candidate INV043 The international Searching Authority considered claims relating to INV043 to be novel, inventive and have industrial applicability The new patent will strengthen and extend the period of global IP protection for PhotosoftTM Stronger IP protection will position Invion well as it prepares for clinical trials using INV043 as a standalone therapy Adds value to potential partnership opportunities with the pharmaceutical industry to develop combination therapies such as the immune checkpoint inhibitor market that is projected to be $141 billion in 20301 MELBOURNE (AUSTRALIA) 08 June 2022: Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce that an International Patent Application, which includes the lead compound INV043, has been published. This patent builds upon previously granted PhotosoftTM related patents in Australia and other territories that Invion has exclusive rights to. The new patent, upon approval, will extend the global intellectual property (IP) protection for the PhotosoftTM technology for another two decades (the original patents are set to expire in 2033). Pre-clinical proof of concept studies of INV043, which is covered by this patent, conducted by Hudson Institute of Medical Research found: ▪ ▪ ▪ INV043 to be effective at ablating multiple types of cancer including triple negative breast cancer (TNBC), pancreatic and T-cell lymphoma Complete regression of established TNBC tumours in mice and provide protective immunity against recurrence of disease following treatment with INV043 Significant improvement in the effectiveness of immune checkpoint inhibitors (ICI), an established type of immunotherapy used in cancer treatment, when used in combination with a restricted administration of INV043. The patent application comes at an important juncture for Invion as the Company is preparing to undertake clinical trials using INV043 to treat cancers and opens up opportunities to combine INV043 with other established cancer therapies to improve patient outcomes. The new patent broadens commercial opportunities for Invion that include both: • • 1 Development of INV043 as a standalone therapy, and Opens partnership opportunities with international pharmaceutical companies to develop combination therapies, such as INV043 and ICI’s, potentially broadening the patient population who can benefit from such treatments. https://www.alliedmarketresearch.com/immune-check-point-inhibitors-market Invion Limited ABN 76 094 730 417 100 Albert Road, South Melbourne, VIC 3205 P: +61 3 9692 7222 W: www.inviongroup.com ASX ANNOUNCEMENT • Has the potential for new IP development that may extend patent protections for ICI therapies, many which are close to expiring. Details on the patent application The newly filed patent covering clinical drug candidate INV043 has now progressed to the international examination phase. The application was filed by licensor and funder, RMW Cho Group Limited, pursuant to the Patent Cooperation Treaty (PCT), as the next phase in obtaining new patents in markets globally, including Australia and other territories that Invion has exclusive commercialising rights to. The findings of the International Search Report and associated Written Opinion from the European Patent Office considered the claims relating to INV043 as novel, inventive and meet the requirements for industrial applicability. “The international patent application will put Invion in a stronger position to commercialise INV043 as a standalone treatment and also through partnerships via combination therapy applications,” said Invion’s Executive Chairman and Chief Executive Officer, Thian Chew. “We believe PhotosoftTM has the potential to revolutionise the way cancers and other diseases are treated. Its unique properties give Invion multiple avenues to realise value for our shareholders.” This announcement was approved for release by Thian Chew, Chairman of the Board. ____________________________________________ Investor and Media enquiries: Thian Chew (Chairman & CEO) T: +61 3 9692 7222 E: investor@inviongroup.com Brendon Lau (Investor & Media Relations) M: +61 409 341 613 E: brendon.lau@inviongroup.com About Invion Invion is a life-science company that is leading the global research and development of the PhotosoftTM technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan, Japan and South Korea to the PhotosoftTM technology for all cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX). About Photodynamic Therapy (PDT) Invion is developing PhotosoftTM technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. Invion Limited ABN 76 094 730 417 100 Albert Road, South Melbourne, VIC 3205 P: +61 3 9692 7222 W: www.inviongroup.com